Open Access

Changes in enteroendocrine and immune cells following colitis induction by TNBS in rats

  • Authors:
    • Magdy El‑Salhy
    • Jan Gunnar Hatlebakk
  • View Affiliations

  • Published online on: October 31, 2016     https://doi.org/10.3892/mmr.2016.5902
  • Pages: 4967-4974
  • Copyright: © El‑Salhy et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Approximately 3.6 million individuals suffer from inflammatory bowel disease (IBD) in the western world, with an annual global incidence rate of 3‑20 cases/100,000 individuals. The etiology of IBD is unknown, and the currently available treatment options are not satifactory for long‑term treatment. Patients with inflammatory bowel disease present with abnormalities in multiple intestinal endocrine cell types, and a number of studies have suggested that interactions between gut hormones and immune cells may serve a pivotal role in the pathophysiology of IBD. The aim of the present study was to investigate alterations in colonic endocrine cells in a rat model of IBD. A total of 30 male Wistar rats were divided into control and trinitrobenzene sulfonic acid (TNBS)‑induced colitis groups. Colonoscopies were performed in the control and TNBS groups at day 3 following the induction of colitis, and colonic tissues were collected from all animals. Colonic endocrine and immune cells in the obtained tissue samples were immunostained and their densities were quantified. The densities of chromogranin A, peptide YY, and pancreatic polypeptide‑producing cells were significantly lower in the TNBS group compared with the control group, whereas the densities of serotonin, oxyntomodulin, and somatostatin‑producing cells were significantly higher in the TNBS group. The densities of mucosal leukocytes, B/T‑lymphocytes, T‑lymphocytes, B‑lymphocytes, macrophages/monocytes and mast cells were significantly higher in the TNBS group compared with the controls, and these differences were strongly correlated with alterations in all endocrine cell types. In conclusion, the results suggest the presence of interactions between intestinal hormones and immune cells.

Introduction

Abnormalities in several intestinal endocrine cell types have been reported in patients with inflammatory bowel disease (IBD) and in animal models of human IBD (120). The association between the neuroendocrine peptides/amines in the gut and the immune system has been previously investigated, and it was suggested that interactions between gut hormones and immune cells may serve a pivotal role in the pathophysiology of IBD (8,10,11,2129).

The etiology of IBD is unknown and the currently available treatments are not completely satisfactory (2,30). Treatment with 5-aminosalicylates and corticosteroids are not effective for the long-term treatment of the majority of patients with IBD. In addition, thiopurine analogues, mercaptopurine and azathioprine, as well as methotrexate, have been used. Short and long-term side effects limit the use of these agents. Biological agents, such as antibodies against tumor necrosis factor α (TNFα), have been used for two decades. However, only ~65% of patients with ulcerative colitis and Crohn's disease respond to treatment with anti-TNFα, and surgery remains the only option for many IBD patients (2,30). Understanding the role of the gut neuroendocrine peptides/amines in the pathophysiology of IBD may provide an insight into its etiology and lead to the use of agonists or antagonists to these peptides and amines as a treatment for IBD (26).

Using a model of human ulcerative colitis (UC) in dextran sulfate sodium (DSS)-induced rats, a recent study demonstrated that abnormalities in the large intestine endocrine cells were strongly correlated with the alterations in immune cells (31). The present study investigated the large intestine endocrine cells in an animal model of Crohn's disease (CD), which involved the induction of colitis in rats using trinitrobenzene sulfonic acid (TNBS). The aim of the current study was to determine whether a change in immune cell number is correlated with abnormalities in the endocrine cells.

Materials and methods

Animal model

A total of 30 male Wistar rats (6 weeks of age; Wistar Hannover GALAS; Taconic Biosciences, Inc., Lille Skensved, Denmark), with a mean body weight of 276 g (range, 235–380 g), were housed in Makrolon III cages with water and food available ad libitum. They were fed a standard diet (B&K Universal AS, Nittedal, Norway) and were maintained at a temperature of 20–22°C, a relative humidity of 50–60% and under 12 h light/dark cycles. Rats were acclimated to these animal house conditions for a minimum of 7 days prior to the start of the experiments. They were then divided equally into the following 2 groups: Control and TNBS-induced colitis.

Induction of colitis with TNBS

Rats were fasted for 24 h prior to TNBS administration. A single dose of TNBS (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) was administered to the colon of each rat (25 mg/animal in a 50% ethanol solution; 0.5 ml/rat) followed by 2 ml air, at 8 cm from the anal margin using an 8.5 cm-long, 2.5-mm-wide round-tipped Teflon feeding tube (AgnTho's AB, Lidingö, Sweden) under isoflurane (Schering-Plough Pharmaceuticals, North Wales, USA) anesthesia. The animals were kept in a prone position with their hind legs raised for at least 2 min following the administration of the TNBS. They were supervised until recovery and then monitored several times daily. The control group received the same treatment as the TNBS group, except that 0.9% saline instead of TNBS was introduced into the colon. Any rats that exhibited signs of pain were injected subcutaneously with 1 ml Temgesic (0.3 mg Temgesic/ml; Merck Sharpe & Dohme, Hoddesdon, UK).

Colonoscopy

Colonoscopies were performed in the control and TNBS rats at 3 days following the administration of 0.9% saline and TNBS, respectively. The bowels were prepared as described previously (32). Briefly, prior to the colonoscopy, the rats were deprived of food for 24 h and received gastric doses of 1 and 2 ml Picoprep (Ferring Holding SA, Saint Prex, Switzerland) followed by 2 ml water at 24 and 12 h, respectively. Picoprep was administered using an 8.5 cm-long, 2.5 mm wide round-tipped Teflon feeding tube (AgnTho's AB). Picoprep (150 ml) contains 10 mg sodium sulfates, 3.5 g magnesium oxide, and 12 g citric acid.

Rats were anesthetized by inhalation of isoflurane (Merck Sharpe & Dohme) prior to and during the colonoscopy. They were placed in a supine position and secured to an acrylic surgical table (World Precision Instruments, Sarasota, FL, USA), and a warming pad (T/Pad; Gaymar Industries, Inc., Orchard Park, NY, USA) with a heat therapy pump (Gaymar TP500 T/Pump; Gaymar Industries, Inc.) was used to maintain normothermia during the procedure. The top of a video gastroscope (GIF-N180; Olympus Corporation, Tokyo, Japan) was lubricated with 2% lidocaine (Xylocaine; AstraZeneca, Södertälje, Sweden) and introduced gently into the anus.

Endoscopic inflammation was scored according to the same grading scale as described by Vermeulen et al (33). This scale comprises the following five subscales (total score, 0–19 points): Degree of inflammation (0–6 points), extent of disease (0–10 points), stenosis (0 or 1 point), edema (0 or 1 point) and active bleeding (0 or 1 point).

Following the procedure, rats were sacrificed by CO2 inhalation and a postmortem laparotomy was conducted. Tissue samples obtained from the distal colon were examined histopathologically, and with immunostaining techniques as described below.

The local ethical committee for experimental animals at the University of Bergen (Bergen, Norway), which is responsible for implementing the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes, approved the protocols employed for the purposes of the current study.

Histopathological and immunohistochemical analysis

Rat colon tissue samples were fixed overnight in 4% buffered paraformaldehyde, embedded in paraffin and sectioned at into 5 µm-sections. The sections were deparaffinized and then stained with hematoxylin-eosin, or immunostained using the ultraView Universal DAB Detection kit (version 1.02.0018; Venata Medical Systems, Inc., Basel, Switzerland) and the BenchMark Ultra IHC/ISH staining module (Venata Medical Systems, Inc.). Tissue sections were incubated with primary antibodies for 32 min at 37°C. Details of the primary antibodies used are listed in Table I.

Table I.

Details of primary antibodies used.

Table I.

Details of primary antibodies used.

Target proteinSpecies raised inTarget speciesDilutionSourceCatalogue number
Chromogranin AMouseaN-terminal of purified chromograninA1:1,000Dako (Glostrup, Denmark)M869
SerotoninMouseaSerotonin1:1,500Dako5HT-209
Peptide YYRabbitbPeptide YY1:1,600Alpha-Diagnostics International (San Antonio, TX, USA)PYY 11A
OxyntomodulinRabbitbPorcine glucagon1:200Acris Antibodies GmbH (Herford, Germany)BP508
PancreaticRabbitbSynthetic human polypeptide polypeptide1:500Diagnostic Bio-Systems (Pleasanton CA, USA)114
SomatostatinRabbitbSynthetic human somatostatin1:800DakoA566
LeukocytesMouseaHuman CD451:600DakoM0701
B/T lymphocytesMouseaHuman CD51:500DakoIS082
T lymphocytesMouseaHuman CD571:200DakoIS647
B lymphocytesMouseaHuman CD231:400DakoIS781
Monocytes and macrophagesMouseaHuman CD681:100DakoM0814
Mast cellsMouseaHuman mast cell tryptase1:800DakoM7052

a and b denote monoclonal and polyclonal primary antibodies, respectively.

Quantification of endocrine and immune cells

The endocrine and immune cells were quantified by manually counting each cell type in 10 randomly selected microscopic fields of view using cellSens imaging software (version 1.7; cellSens; Olympus Corporation). The number of endocrine cells in the lining epithelium, and the number of immune cells in the lamina propria were manually counted in each field using a computer mouse. To achieve this, the epithelial cell area was determined by manually drawing an enclosed region with the computer mouse. A ×40 objective was used, which, represented a tissue area of 0.035 mm2 for each frame (field) on the monitor. The data are presented as the number of endocrine cells/mm2 of epithelium, and the number of immune cells/field of view. Immunostained sections were coded and mixed, and measurements were determined by the same person (Professor Magdy El-Salhy), who was unaware of which group the slides were derived from.

Statistical analysis

Differences between the control and TNBS groups were analyzed using the nonparametric Mann-Whitney U test. The existence of a correlation between abnormalities/alterations in the densities of endocrine cells and immune cells was determined using the nonparametric Spearman's rank correlation test. The data are presented as the mean ± standard error of the mean. P<0.05 was considered to indicate a statistically significant difference.

Results

Histopathological examination

Histopathological examination of the colonic tissues demonstrated that those derived from control rats displayed a normal histology, whereas those from the TNBS group exhibited an abnormal mucosal architecture, the presence of crypt abscesses, edema, bleeding and infiltration of immune cells into the mucosa and submucosa (Fig. 1).

Colonoscopy

Rat colons in the control group displayed a normal appearance with undamaged mucosa and clear branching of blood vessels, whereas the colonic mucosa in the TNBS group exhibited patchy and discontinuous erythema, edema and occasional hemorrhage (Fig. 2). In addition, aphthoid ulcers abruptly surrounded by normal mucosa were observed in the colons of TNBS rats (Fig. 2B). The deep ulcerations coalesced, which led to mucosal detachment and the presence of few mucosal islands. Ulcerated stenosis was also observed in TNBS rat colons (Fig. 2B). The endoscopic inflammation scores were 0 and 6.4±0.8 in the control and TNBS groups, respectively.

Endocrine cells

The densities of various endocrine cells are presented in Figs. 3, 4 and 5. The density of chromogranin A (CgA), peptide YY (PYY) and pancreatic polypeptide (PP) staining was reduced in the colon tissues from rats in the TNBS group compared with those of the control group (P<0.0001, P<0.0001 and P=0.0002, respectively; Fig. 3). In contrast, serotonin oxyntomodulin and somatostatin densities were increased in the colon tissues from the TNBS group compared with those of the controls (P<0.0001, P<0.0001 and P=0.01, respectively; Fig. 3).

Immune cells

As presented in Figs. 1 and 6, the densities of all types of immune cells were significantly greater in the TNBS group compared with the control group [leukocytes, 5.9±0.4 vs. 23.3±2.2 cells/field (P<0.0001); B/T lymphocytes, 9.0±0.7 vs. 35.8±2.3 cells/field (P<0.0001); T lymphocytes, 10.5±0.6 vs. 26.6±2.9 cells/field (P<0.0001); B lymphocytes, 9.7±0.4 vs. 27.7±2.6 cells/field (P<0.0001); macrophages/monocytes, 7.6±0.7 vs. 909.0±46.3 cells/field (P<0.0001); and mast cells 5.5±0.5 vs. 27.3±2.9 cells/field (P<0.0001)].

Correlation between endocrine and immune cells

The Spearman correlation coefficients and P-values for the correlations between different endocrine cell types and various immune cells are presented in Table II. The number of CgA, PYY, and PP-producing immune cells was observed to be negatively correlated with the number of specific types of immune cells, whilst positive correlations were observed for serotonin, oxyntomodulin, and somatostatin cells.

Table II.

Spearman's rank correlation coefficients (r) and P-values for the association between endocrine and immune cells in rats with TNBS-induced colitis.

Table II.

Spearman's rank correlation coefficients (r) and P-values for the association between endocrine and immune cells in rats with TNBS-induced colitis.

Immune cell type

Endocrine cell typeLeukocytesB/T lymphocytesT lymphocytesB lymphocytes Macrophages/monocytesMast cells
Chromogranin Ar=−0.7r=−0.3r=−0.6r=−0.6r=−0.7r=−0.5
P=0.04P=0.09P=0.009P=0.02P=0.008P=0.03
Serotoninr=0.7r=0.7r=0.4r=0.6r=0.2r=0.4
P=0.005P=0.009P=0.01P=0.02P=0.05P=0.1
Peptide YYr=−0.5r=−0.7r=0.2r=−0.7r=−0.6r=0.7
P=0.04P=0.002P=0.06P=0.002P=0.02P=0.7
Oxyntomdulinr=0.2r=0.5r=0.6r=0.1r=0.1r=−0.6
P=0.6P=0.02P=0.01P=0.7P=0.9P=0.02
Pancreatic polypeptider=−0.7r=−0.5r=−0.2r=−0.6r=−0.6r=−0.7
P=0.004P=0.8P=0.5P=0.008P=0.01P=0.002
Somatostatinr=0.6r=0.7r=0.1r=0.2r=−0.7r=−0.6
P=0.02P=0.8P=0.7P=0.6P=0.0044P=0.02

Discussion

TNBS-induced colitis in rats closely mimics human CD (3439). Although this model exhibits clinical and morphological features similar to human CD (3941), it lacks the chronicity observed in human CD (39). The present study observed that the frequency of all types of colonic endocrine cells was affected in rats with TNBS-induced colitis. In addition, abnormalities in the colonic endocrine cells were strongly correlated with the alterations in the number of different types of immune cells following the induction of colitis. These observations support the previously suggested role of gut hormones in immune activation and inflammation (21,22,42).

In the present study, the alterations in the number of colonic endocrine cells observed in rats with TNBS-induced colitis differ from those observed in rats with DSS-induced colitis in a previous study (31). In TNBS and DSS-induced colitis, the densities of serotonin and oxyntomodulin were increased, while the density of PP was reduced compared with normal controls. However, the CgA and PYY-producing immune cell densities were increased in DSS-induced colitis, whereas they were reduced in TNBS-induced colitis compared with normal controls. In addition, the density of somatostatin was reduced in DSS-induced colitis (31), however was increased in TNBS-induced colitis in the present study. Differences in the alterations of the number of colonic endocrine cells between CD and UC have been reported previously by El Salhy et al (1). This study demonstrated that the densities of CgA and serotonin were increased in CD and UC, while the densities of PYY and PP were reduced, and oxyntomodulin was decreased in CD only.

Although the abnormalities in the colonic endocrine cells in DSS-induced colitis were strongly correlated with leukocytes, B lymphocytes, T lymphocytes, macrophages/monocytes and mast cells (31), the results for TNBS-induced colitis in the present study demonstrated that specific endocrine cell types were correlated with particular immune cell types. CgA is a member of the granin family (43,44), which is localized to gut endocrine cells (4548), and is considered to be a common marker for gastrointestinal endocrine cells (49,50). The reduction in the density of CgA-producing cells observed in the present study may reflect reductions in the densities of all colonic endocrine cells following the induction of colitis by TNBS. The density of CgA-producing cells was negatively correlated with increases in all immune cell types except for B/T lymphocytes. CgA suppresses the release of interleukin (IL)-16 and IL-5, and consequently reduces the number of lymphocytes at sites of inflammation, and reduces the pro-inflammatory actions of lymphocytes and monocytes (5153). In addition, CgA, inhibits the vascular leakage caused by tumor necrosis factor-α (54). CgA is generally considered to exert an anti-inflammatory effect (54). It can therefore be speculated that the reduced density of CgA results from a direct action exerted by immune cells.

In the present study, the observed increase in the density of colonic serotonin-producing cells in TNBS-induced colitis relative to controls is consistent with previous observations in patients with UC, CD and microscopic colitis, as well as animal models of colitis (1,3,5557). The increased density of serotonin-producing cells in the present study was correlated with increases in the number of all types of immune cells examined, apart from macrophages/monocytes and mast cells. Lymphocytes, macrophages, and dendritic cells express serotonin receptors (58), and IL-13 receptors have been localized on serotonin cells (59). In addition, serotonin inhibits the apoptosis of immune cells, promotes the recruitment of T cells, affects the proliferation of lymphocytes and protects natural killer cells (6063). Furthermore, a previous study demonstrated that there are fewer serotonin-producing cells in mice lacking T-lymphocyte receptors (51). Serotonin stimulates gastric and intestinal motility, and intestinal secretion (64,65). Therefore, the increase in serotonin may accelerate gastrointestinal motility and increase intestinal secretion thus resulting in diarrhea, which is the primary symptom in TNBS-induced colitis.

PYY is colocalized with oxyntomodulin in endocrine L cells (66,67). In the present study, the density of PYY reduced while oxyntomodulin increased, which indicates that L cells downregulate the expression of PYY, but upregulate the expression of oxyntomodulin in TNBS-induced colitis in rats. PYY stimulates the adhesion of macrophages, chemotaxis, phagocytosis and the production of superoxide anions (68). PYY mRNA has been detected in mouse macrophages (69). The precise interaction between oxyntomodulin and immune cells has not yet been determined. In the present study, the density of PYY cells was negatively correlated with increases in the number of B/T lymphocytes, B lymphocytes and macrophages/monocytes, whereas oxyntomodulin density was positively correlated with B/T lymphocytes, T lymphocytes, and mast cells. These results indicate the presence different interactions of PYY and oxyntomodulin with immune cells. PYY delays gastric emptying, is a pivotal mediator of the ileal brake, and stimulates the absorption of water and electrolytes (70). The reduction in the number of PYY-producing cells observed in the current study may have contributed to the acceleration of gastrointestinal motility and increased intestinal secretion observed in TNBS-induced colitis.

The reduction in the number of PP-producing cells observed in the current study is consistent with previous reports for UC and CD (1). However, the interaction between PP and immune cells remains to be fully elucidated. In the present study, PP density was negatively correlated with the number of B lymphocytes, macrophages/monocytes and mast cells. PP stimulates gastric acid secretion and the motility of the stomach and small intestine in addition to relaxing the gallbladder (64). The increased density of somatostatin cells in TNBS-induced colitis observed in the present study contradicts previous observations of UC, CD and DSS-induced colitis, where somatostatin cell density was reported to reduce (1,19,20). Somatostatin inhibits lymphocyte proliferation, immunoglobulin synthesis and the release of neutrophil elastase (7175). In the present study, the density of somatostatin-producing cells was observed to be positively correlated with the number of macrophages/monocytes and mast cells. The strong correlation observed between alterations in PP and somatostatin-producing cell densities and specific immune cell types, indicate that they may be involved in the inflammatory process.

The present observations, demonstrating that alterations in the number of immune cells are strongly correlated with alterations in large intestinal cells in an animal model of human of Crohn's disease, support the debated suggestion of an interaction between intestinal hormones and the gut immune system. Understanding this interaction may improve our understanding of the pathophysiological mechanisms involved in IBD, and may provide us with novel therapeutic approaches to treat this condition.

Acknowledgements

The present study was supported by grants from the Helse-Vest regional health authority, (Bergen, Norway; grant no. 911978) and Helse-Fonna health organization (Haugesund, Norway; grant no. 40415).

References

1 

El-Salhy M, Danielsson A, Stenling R and Grimelius L: Colonic endocrine cells in inflammatory bowel disease. J Intern Med. 242:413–419. 1997. View Article : Google Scholar : PubMed/NCBI

2 

El-Salhy M, Gundersen D, Hatlebakk JG and Hausken T: Chromogranin a cell density as a diagnostic marker for lymphocytic colitis. Dig Dis Sci. 57:3154–3159. 2012. View Article : Google Scholar : PubMed/NCBI

3 

El-Salhy M, Gundersen D, Hatlebakk JG and Hausken T: High densities of serotonin and peptide YY cells in the colon of patients with lymphocytic colitis. World J Gastroenterol. 18:6070–6075. 2012. View Article : Google Scholar : PubMed/NCBI

4 

El-Salhy M, Lomholt-Beck B and Gundersen TD: High chromogranin A cell density in the colon of patients with lymphocytic colitis. Mol Med Rep. 4:603–605. 2011.PubMed/NCBI

5 

Moran GW, Pennock J and McLaughlin JT: Enteroendocrine cells in terminal ileal Crohn's disease. J Crohns Colitis. 6:871–880. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Moran GW, Leslie FC and McLaughlin JT: Crohn's disease affecting the small bowel is associated with reduced appetite and elevated levels of circulating gut peptides. Clin Nutr. 32:404–411. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Besterman HS, Mallinson CN, Modigliani R, Christofides ND, Pera A, Ponti V, Sarson DL and Bloom SR: Gut hormones in inflammatory bowel disease. Scand J Gastroenterol. 18:845–852. 1983. View Article : Google Scholar : PubMed/NCBI

8 

El-Salhy M, Mazzawi T, Gundersen D, Hatlebakk JG and Hausken T: The role of peptide YY in gastrointestinal diseases and disorders (Review). Int J Mol Med. 31:275–282. 2013.PubMed/NCBI

9 

Hirotani Y, Mikajiri K, Ikeda K, Myotoku M and Kurokawa N: Changes of the peptide YY levels in the intestinal tissue of rats with experimental colitis following oral administration of mesalazine and prednisolone. Yakugaku Zasshi. 128:1347–1353. 2008. View Article : Google Scholar : PubMed/NCBI

10 

Vona-Davis LC and McFadden DW: NPY family of hormones: Clinical relevance and potential use in gastrointestinal disease. Curr Top Med Chem. 7:1710–1720. 2007. View Article : Google Scholar : PubMed/NCBI

11 

El-Salhy M, Suhr O and Danielsson A: Peptide YY in gastrointestinal disorders. Peptides. 23:397–402. 2002. View Article : Google Scholar : PubMed/NCBI

12 

Tari A, Teshima H, Sumii K, Haruma K, Ohgoshi H, Yoshihara M, Kajiyama G and Miyachi Y: Peptide YY abnormalities in patients with ulcerative colitis. Jpn J Med. 27:49–55. 1988. View Article : Google Scholar : PubMed/NCBI

13 

Sciola V, Massironi S, Conte D, Caprioli F, Ferrero S, Ciafardini C, Peracchi M, Bardella MT and Piodi L: Plasma chromogranin a in patients with inflammatory bowel disease. Inflamm Bowel Dis. 15:867–871. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Bishop AE, Pietroletti R, Taat CW, Brummelkamp WH and Polak JM: Increased populations of endocrine cells in Crohn's ileitis. Virchows Arch A Pathol Anat Histopathol. 410:391–396. 1987. View Article : Google Scholar : PubMed/NCBI

15 

Manocha M and Khan WI: Serotonin and GI disorders: An update on clinical and experimental studies. Clin Transl Gastroenterol. 3:e132012. View Article : Google Scholar : PubMed/NCBI

16 

Stoyanova II and Gulubova MV: Mast cells and inflammatory mediators in chronic ulcerative colitis. Acta Histochem. 104:185–192. 2002. View Article : Google Scholar : PubMed/NCBI

17 

Yamamoto H, Morise K, Kusugami K, Furusawa A, Konagaya T, Nishio Y, Kaneko H, Uchida K, Nagai H, Mitsuma T and Nagura H: Abnormal neuropeptide concentration in rectal mucosa of patients with inflammatory bowel disease. J Gastroenterol. 31:525–532. 1996. View Article : Google Scholar : PubMed/NCBI

18 

Payer J, Huorka M, Duris I, Mikulecky M, Kratochvílová H, Ondrejka P and Lukác L: Plasma somatostatin levels in ulcerative colitis. Hepatogastroenterology. 41:552–553. 1994.PubMed/NCBI

19 

Watanabe T, Kubota Y, Sawada T and Muto T: Distribution and quantification of somatostatin in inflammatory disease. Dis Colon Rectum. 35:488–494. 1992. View Article : Google Scholar : PubMed/NCBI

20 

Koch TR, Carney JA, Morris VA and Go VL: Somatostatin in the idiopathic inflammatory bowel diseases. Dis Colon Rectum. 31:198–203. 1988. View Article : Google Scholar : PubMed/NCBI

21 

Khan WI and Ghia JE: Gut hormones: Emerging role in immune activation and inflammation. Clin Exp Immunol. 161:19–27. 2010.PubMed/NCBI

22 

Margolis KG and Gershon MD: Neuropeptides and inflammatory bowel disease. Curr Opin Gastroenterol. 25:503–511. 2009. View Article : Google Scholar : PubMed/NCBI

23 

Bampton PA and Dinning PG: High resolution colonic manometry-what have we learnt?-A review of the literature 2012. Curr Gastroenterol Rep. 15:3282013. View Article : Google Scholar : PubMed/NCBI

24 

Ameri P and Ferone D: Diffuse endocrine system, neuroendocrine tumors and immunity: What's new? Neuroendocrinology. 95:267–276. 2012. View Article : Google Scholar : PubMed/NCBI

25 

Farzi A, Reichmann F and Holzer P: The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour. Acta Physiol (Oxf). 213:603–627. 2015. View Article : Google Scholar : PubMed/NCBI

26 

El-Salhy M and Hausken T: The role of the neuropeptide Y (NPY) family in he pathophysiology of inflammatory bowel disease (IBD). Neuropeptides. 55:137–144. 2016. View Article : Google Scholar : PubMed/NCBI

27 

Wheway J, Herzog H and Mackay F: NPY and receptors in immune and inflammatory diseases. Curr Top Med Chem. 7:1743–1752. 2007. View Article : Google Scholar : PubMed/NCBI

28 

Wheway J, Herzog H and Mackay F: The Y1 receptor for NPY: A key modulator of the adaptive immune system. Peptides. 28:453–458. 2007. View Article : Google Scholar : PubMed/NCBI

29 

Wheway J, Mackay CR, Newton RA, Sainsbury A, Boey D, Herzog H and Mackay F: A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med. 202:1527–1538. 2005. View Article : Google Scholar : PubMed/NCBI

30 

El-Salhy M, Gundersen D, Hatlebakk JG and Hausken T: Clinical presentation, diagnosis, pathogenesis and treatment options for lymphocytic colitis (Review). Int J Mol Med. 32:263–270. 2013.PubMed/NCBI

31 

El-Salhy M, Hatlebakk JG and Gilja OH: The abnormalities in endocrine and immune cells are correlated in dextran-sulfate-sodium-induced colitis. Mol Med Rep. in press. 2016.

32 

El-Salhy M, Umezawa K, Gilja OH, Hatlebakk JG, Gundersen D and Hausken T: Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in Rats. Sci World J. 2014:1–8. 2014. View Article : Google Scholar

33 

Vermeulen W, De Man JG, Nullens S, Pelckmans PA, De Winter BY and Moreels TG: The use of colonoscopy to follow the inflammatory time course of TNBS colitis in rats. Acta Gastroenterol Belg. 74:304–311. 2011.PubMed/NCBI

34 

Saleh M and Elson CO: Experimental inflammatory bowel disease: Insights into the host-microbiota dialog. Immunity. 34:293–302. 2011. View Article : Google Scholar : PubMed/NCBI

35 

Carter MJ, Lobo AJ and Travis SP: IBD Section, British Society of Gastroenterology: Guidelines for the management of inflammatory bowel disease in adults. Gut. 53:(Suppl 5). V1–V16. 2004. View Article : Google Scholar : PubMed/NCBI

36 

Sands BE: New therapies for the treatment of inflammatory bowel disease. Surg Clin North Am. 86:1045–1064. 2006. View Article : Google Scholar : PubMed/NCBI

37 

Lopez A, Billioud V, Peyrin-Biroulet C and Peyrin-Biroulet L: Adherence to anti-TNF therapy in inflammatory bowel diseases: A systematic review. Inflamm Bowel Dis. 19:1528–1533. 2013. View Article : Google Scholar : PubMed/NCBI

38 

Danese S, Semeraro S, Armuzzi A, Papa A and Gasbarrini A: Biological therapies for inflammatory bowel disease: Research drives clinics. Mini Rev Med Chem. 6:771–784. 2006. View Article : Google Scholar : PubMed/NCBI

39 

Elson CO, Sartor RB, Tennyson GS and Riddell RH: Experimental models of inflammatory bowel disease. Gastroenterology. 109:1344–1367. 1995. View Article : Google Scholar : PubMed/NCBI

40 

Dieleman LA, Palmen MJ, Akol H, Bloemena E, Peña AS, Meuwissen SG and Van Rees EP: Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 114:385–391. 1998. View Article : Google Scholar : PubMed/NCBI

41 

Low D, Nguyen DD and Mizoguchi E: Animal models of ulcerative colitis and their application in drug research. Drug Des Devel Ther. 7:1341–1357. 2013.PubMed/NCBI

42 

Öhman L, Törnblom H and Simrén M: Crosstalk at the mucosal border: Importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol. 12:36–49. 2015. View Article : Google Scholar : PubMed/NCBI

43 

Buffa R, Mare P, Gini A and Salvadore M: Chromogranins A and B and secretogranin II in hormonally identified endocrine cells of the gut and the pancreas. Basic Appl Histochem. 32:471–484. 1988.PubMed/NCBI

44 

Eiden LE: Is chromogranin a prohormone? Nature. 325:3011987. View Article : Google Scholar : PubMed/NCBI

45 

Buffa R, Capella C, Fontana P, Usellini L and Solcia E: Types of endocrine cells in the human colon and rectum. Cell Tissue Res. 192:227–240. 1978. View Article : Google Scholar : PubMed/NCBI

46 

Curry WJ, Johnston CF, Hutton JC, Arden SD, Rutherford NG, Shaw C and Buchanan KD: The tissue distribution of rat chromogranin A-derived peptides: Evidence for differential tissue processing from sequence specific antisera. Histochemistry. 96:531–538. 1991. View Article : Google Scholar : PubMed/NCBI

47 

Portela-Gomes GM and Stridsberg M: Selective processing of chromogranin A in the different islet cells in human pancreas. J Histochem Cytochem. 49:483–490. 2001. View Article : Google Scholar : PubMed/NCBI

48 

Portela-Gomes GM and Stridsberg M: Chromogranin A in the human gastrointestinal tract: An immunocytochemical study with region-specific antibodies. J Histochem Cytochem. 50:1487–1492. 2002. View Article : Google Scholar : PubMed/NCBI

49 

Taupenot L, Harper KL and O'Connor DT: The chromogranin-secretogranin family. N Engl J Med. 348:1134–1149. 2003. View Article : Google Scholar : PubMed/NCBI

50 

Wiedenmann B and Huttner WB: Synaptophysin and chromogranins/secretogranins-widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Arch B Cell Pathol Incl Mol Pathol. 58:95–121. 1989. View Article : Google Scholar : PubMed/NCBI

51 

Spiller R: Serotonin and GI clinical disorders. Neuropharmacology. 55:1072–1080. 2008. View Article : Google Scholar : PubMed/NCBI

52 

Egger M, Beer AG, Theurl M, Schgoer W, Hotter B, Tatarczyk T, Vasiljevic D, Frauscher S, Marksteiner J, Patsch JR, et al: Monocyte migration: A novel effect and signaling pathways of catestatin. Eur J Pharmacol. 598:104–111. 2008. View Article : Google Scholar : PubMed/NCBI

53 

Feistritzer C, Mosheimer BA, Colleselli D, Wiedermann CJ and Kähler CM: Effects of the neuropeptide secretoneurin on natural killer cell migration and cytokine release. Regul Pept. 126:195–201. 2005. View Article : Google Scholar : PubMed/NCBI

54 

Ferrero E, Magni E, Curnis F, Villa A, Ferrero ME and Corti A: Regulation of endothelial cell shape and barrier function by chromogranin A. Ann N Y Acad Sci. 971:355–358. 2002. View Article : Google Scholar : PubMed/NCBI

55 

Bertrand PP and Bertrand RL: Serotonin release and uptake in the gastrointestinal tract. Auton Neurosci. 153:47–57. 2010. View Article : Google Scholar : PubMed/NCBI

56 

Qian BF, El-Salhy M, Melgar S, Hammarström ML and Danielsson A: Neuroendocrine changes in colon of mice with a disrupted IL-2 gene. Clin Exp Immunol. 120:424–433. 2000. View Article : Google Scholar : PubMed/NCBI

57 

Oshima S, Fujimura M and Fukimiya M: Changes in number of serotonin-containing cells and serotonin levels in the intestinal mucosa of rats with colitis induced by dextran sodium sulfate. Histochem Cell Biol. 112:257–263. 1999. View Article : Google Scholar : PubMed/NCBI

58 

Cloëz-Tayarani I and Changeux JP: Nicotine and serotonin in immune regulation and inflammatory processes: A perspective. J Leukoc Biol. 81:599–606. 2007. View Article : Google Scholar : PubMed/NCBI

59 

Wang H, Steeds J, Motomura Y, Deng Y, Verma-Gandhu M, El-Sharkawy RT, McLaughlin JT, Grencis RK and Khan W: CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection. Gut. 56:949–957. 2007. View Article : Google Scholar : PubMed/NCBI

60 

Stefulj J, Cicin-Sain L, Schauenstein K and Jernej B: Serotonin and immune response: Effect of the amine on in vitro proliferation of rat lymphocytes. Neuroimmunomodulation. 9:103–108. 2001. View Article : Google Scholar : PubMed/NCBI

61 

Betten A, Dahlgren C, Hermodsson S and Hellstrand K: Serotonin protects NK cells against oxidatively induced functional inhibition and apoptosis. J Leukoc Biol. 70:65–72. 2001.PubMed/NCBI

62 

Laberge S, Cruikshank WW, Beer DJ and Center DM: Secretion of IL-16 (lymphocyte chemoattractant factor) from serotonin-stimulated CD8+ T cells in vitro. J Immunol. 156:310–315. 1996.PubMed/NCBI

63 

Soga F, Katoh N, Inoue T and Kishimoto S: Serotonin activates human monocytes and prevents apoptosis. J Invest Dermatol. 127:1947–1955. 2007. View Article : Google Scholar : PubMed/NCBI

64 

El-Salhy M, Seim I, Chopin L, Gundersen D, Hatlebakk JG and Hausken T: Irritable bowel syndrome: The role of gut neuroendocrine peptides. Front Biosci (Elite Ed). 4:2783–2800. 2012.PubMed/NCBI

65 

El-Salhy M: Irritable bowel syndrome: Diagnosis, pathogenesis and treatment options. World J Gastroenterol. 18:5151–5163. 2012.PubMed/NCBI

66 

Spångéus A, Forsgren S and el-Salhy M: Does diabetic state affect co-localization of peptide YY and enteroglucagon in colonic endocrine cells? Histol Histopathol. 15:37–41. 2000.PubMed/NCBI

67 

Pyarokhil AH, Ishihara M, Sasaki M and Kitamura N: The developmental plasticity of colocalization pattern of peptide YY and glucagon-like peptide-1 in the endocrine cells of bovine rectum. Biomed Res. 33:35–38. 2012. View Article : Google Scholar : PubMed/NCBI

68 

De la Fuente M, Bernaez I, Del Rio M and Hernanz A: Stimulation of murine peritoneal macrophage functions by neuropeptide Y and peptide YY. Involvement of protein kinase C. Immunology. 80:259–265. 1993.PubMed/NCBI

69 

Macia L, Yulyaningsih E, Pangon L, Nguyen AD, Lin S, Shi YC, Zhang L, Bijker M, Grey S, Mackay F, et al: Neuropeptide Y1 receptor in immune cells regulates inflammation and insulin resistance associated with diet-induced obesity. Diabetes. 61:3228–3238. 2012. View Article : Google Scholar : PubMed/NCBI

70 

El-Salhy M, Gundersen D, Gilja OH, Hatlebakk JG and Hausken T: Is irritable bowel syndrome an organic disorder? World J Gastroenterol. 20:384–400. 2014. View Article : Google Scholar : PubMed/NCBI

71 

Payan DG, Hess CA and Goetzl EJ: Inhibition by somatostatin of the proliferation of T-lymphocytes and Molt-4 lymphoblasts. Cell Immunol. 84:433–438. 1984. View Article : Google Scholar : PubMed/NCBI

72 

Adeyemi EO, Savage AP, Bloom SR and Hodgson HJ: Somatostatin inhibits neutrophil elastase release in vitro. Peptides. 11:869–871. 1990. View Article : Google Scholar : PubMed/NCBI

73 

Stanisz AM, Befus D and Bienenstock J: Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer's patches, mesenteric lymph nodes, and spleen. J Immunol. 136:152–156. 1986.PubMed/NCBI

74 

Scicchitano R, Dazin P, Bienenstock J, Payan DG and Stanisz AM: Distribution of somatostatin receptors on murine spleen and Peyer's patch T and B lymphocytes. Brain Behav Immun. 1:173–184. 1987. View Article : Google Scholar : PubMed/NCBI

75 

Scicchitano R, Stanisz AM, Payan DG, Kiyono H, McGhee JR and Bienenstock J: Expression of substance P and somatostatin receptors on a T helper cell line. Adv Exp Med Biol 216A. 185–190. 1987. View Article : Google Scholar

Related Articles

Journal Cover

December-2016
Volume 14 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
El‑Salhy M and El‑Salhy M: Changes in enteroendocrine and immune cells following colitis induction by TNBS in rats. Mol Med Rep 14: 4967-4974, 2016
APA
El‑Salhy, M., & El‑Salhy, M. (2016). Changes in enteroendocrine and immune cells following colitis induction by TNBS in rats. Molecular Medicine Reports, 14, 4967-4974. https://doi.org/10.3892/mmr.2016.5902
MLA
El‑Salhy, M., Hatlebakk, J. G."Changes in enteroendocrine and immune cells following colitis induction by TNBS in rats". Molecular Medicine Reports 14.6 (2016): 4967-4974.
Chicago
El‑Salhy, M., Hatlebakk, J. G."Changes in enteroendocrine and immune cells following colitis induction by TNBS in rats". Molecular Medicine Reports 14, no. 6 (2016): 4967-4974. https://doi.org/10.3892/mmr.2016.5902